Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus.
Responses of cytotoxic T-cells (Tc) to human cytomegalovirus (CMV) represent the predominant mechanism by which hosts resist CMV infection. The CMV major immediate-early protein (IE) is present throughout the virus replicative cycle. Studies were performed to determine whether Tc specific for IE effectively lyse CMV-infected targets and are thus capable of providing protective immunity against infection. After in vitro stimulation of peripheral blood mononuclear cells with CMV-infected autologous fibroblasts, Tc specific for IE were not readily detectable in CMV-reactive polyclonal Tc lines. However, after stimulation of peripheral blood mononuclear cells with cells selectively expressing IE, weak but detectable IE-specific Tc responses were observed. The frequency of IE-specific Tc clones derived from cultures stimulated with IE-expressing cells was 50 to 100 times lower than the frequency of Tc clones specific for other CMV proteins isolated from cultures stimulated with CMV-infected cells. All of the IE-specific Tc clones, which efficiently lysed targets selectively expressing IE, demonstrated minimal lysis of CMV-infected fibroblasts, despite abundant IE expression in these target cells. In contrast to these results with IE, other viral proteins were efficiently presented during all phases of CMV infection. These data suggest that CMV has evolved a unique mechanism for selectively limiting the presentation of the potentially immunogenic IE protein, which may preclude IE-specific Tc from providing protective immunity to CMV infection.
Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98104.
M J
MJ
Gilbert
S R
SR
Riddell
C R
CR
Li
P D
PD
Greenberg
D000938:Antigen-Presenting Cells / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology; D000956:Antigens, Viral / Q000096:biosynthesis / Q000276:immunology*; D002478:Cells, Cultured; D002999:Clone Cells; D003587:Cytomegalovirus / Q000254:growth & development / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005805:Genes, MHC Class I / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D017874:Immediate-Early Proteins; D007371:Interferon-gamma / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014762:Viral Interference
D000954:Antigens, Surface; D000956:Antigens, Viral; D006680:HLA Antigens; D017874:Immediate-Early Proteins; C044582:immediate-early proteins, cytomegalovirus; D007371:Interferon-gamma